Ipamorelin: Selective Growth Hormone Secretagogue Research
Mechanism of Action
Clinical Evidence
Last Updated: May 2026
Ipamorelin is a synthetic pentapeptide GH secretagogue distinguished from earlier GHS compounds by its exceptional selectivity: it produces robust growth hormone release via GHS-R1a without the cortisol, ACTH, and prolactin co-stimulation that characterises broader-spectrum compounds such as GHRP-2. First characterised by Raun and colleagues in a landmark 1998 paper in the European Journal of Endocrinology, Ipamorelin represented a step-change in GH secretagogue pharmacology — demonstrating that GHS-R1a agonism could be decoupled from HPA axis activation through structural refinement. Ipamorelin is frequently studied alongside CJC-1295+DAC to produce dual-pathway GH axis activation, and is available alongside GHRP-2 as part of the GH secretagogue compound class.
Key Takeaways
- Ipamorelin is a pentapeptide (5 amino acids: Aib-His-D-2Nal-D-Phe-Lys-NH2) GHS-R1a agonist with molecular weight of 711 Da
- Raun et al. (1998) established that Ipamorelin produces GH release without significant ACTH or cortisol elevation — in contrast to GHRP-2 and GHRP-6
- The selectivity advantage arises from the N-terminal Aib substitution, which modifies receptor engagement geometry to preferentially activate somatotroph GHS-R1a
- Combined with CJC-1295+DAC, Ipamorelin produces synergistic GH amplification via simultaneous GHRH-R + GHS-R1a engagement — the preferred dual-pathway research model
- Available as a research chemical in the UK; not a controlled substance under MDA 1971; for laboratory research use only
Research-Grade Ipamorelin — UK Supply
10MG vials. 99%+ purity HPLC verified. Batch-specific COA. Rapid dispatch.
What Is Ipamorelin? Structure and Classification
Ipamorelin (INN: ipamorelin) is a pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH2, where Aib denotes α-aminoisobutyric acid. It was developed in the late 1990s by Novo Nordisk researchers as part of a systematic effort to identify GHS-R1a agonists with improved selectivity over the earlier GHRP class of compounds (GHRP-2, GHRP-6). The compound belongs to the growth hormone secretagogue (GHS) family — synthetic compounds that mimic and amplify the GH-releasing action of ghrelin, the endogenous GHS-R1a ligand.
At 711 daltons, Ipamorelin is one of the smaller GHS peptides. Its five-amino-acid backbone is stabilised by the D-form amino acids at positions 3 and 4 (D-2-naphthylalanine and D-phenylalanine), which confer resistance to proteolytic degradation and anchor the peptide’s bioactive conformation. The C-terminal amide (-Lys-NH2) further stabilises the molecule against enzymatic cleavage. Estimated serum half-life in research models is 30–60 minutes — substantially shorter than CJC-1295+DAC but longer than unmodified peptides of comparable size.
The Aib Substitution: Why Ipamorelin Is Selective
The defining structural feature of Ipamorelin relative to GHRP-2 is the N-terminal Aib (α-aminoisobutyric acid) substitution. In GHRP-2, the equivalent position is occupied by a histidine residue that participates in GHS-R1a binding across multiple cell types including corticotrophs. The Aib substitution modifies the N-terminal geometry in a way that preserves high-affinity binding at somatotroph GHS-R1a while substantially reducing receptor engagement at corticotroph GHS-R1a. The precise molecular basis — involving differential receptor conformational states or accessory protein interactions — remains an active area of GPCR pharmacology investigation, but the functional consequence is clear and reproducible in published research: somatotroph-selective GH release without corticotroph co-stimulation.
Mechanism of Action: GHS-R1a Agonism and GH Release
Ipamorelin’s primary mechanism is binding to and activating GHS-R1a (Growth Hormone Secretagogue Receptor type 1a) — the cognate receptor for ghrelin — on somatotroph cells in the anterior pituitary gland. GHS-R1a is a Gq/11-coupled GPCR. Ligand binding triggers the Gq alpha subunit to activate phospholipase C-beta (PLCβ), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
IP3 binds IP3 receptors on the endoplasmic reticulum, triggering calcium release into the cytoplasm. DAG, together with elevated intracellular calcium, activates protein kinase C (PKC). The combined effect of elevated cytoplasmic calcium and PKC activation drives exocytosis of GH-containing secretory granules from the somatotroph. The resulting GH pulse typically peaks within 15–30 minutes and resolves within 90–120 minutes in research models — a sharp, transient profile reflecting the relatively short half-life of the peptide.
Hypothalamic Action: Somatostatin Suppression
GHS-R1a is expressed not only on pituitary somatotrophs but also on arcuate nucleus neurons in the hypothalamus. Ipamorelin’s engagement of these hypothalamic GHS-R1a receptors suppresses somatostatin (SRIF) release from the periventricular nucleus — removing the primary inhibitory brake on GH pulsatility. This dual action (direct pituitary stimulation + hypothalamic somatostatin suppression) amplifies the overall GH response beyond what pituitary-only agonism would produce. The hypothalamic component contributes to the synergistic interaction with GHRH analogues.
When Novo Nordisk researchers tested Ipamorelin against GHRP-6 in pig models in the mid-1990s, the GH response magnitudes were comparable — but the cortisol and ACTH curves told a different story. GHRP-6 produced significant HPA axis co-stimulation alongside its GH release; Ipamorelin produced essentially none. This finding — that GHS-R1a agonism and HPA axis co-stimulation were pharmacologically separable — changed the conceptual framework for GHS drug development and positioned Ipamorelin as the template for the next generation of selective GH secretagogues.
Key Research: Raun et al. 1998 — The Selectivity Study
The foundational published research on Ipamorelin is Raun et al. (1998), published in the European Journal of Endocrinology. This paper characterised Ipamorelin’s GH-releasing activity, potency, and selectivity profile relative to GHRP-6 in pig models. The key findings were:
- Ipamorelin produced GH release comparable in magnitude to GHRP-6 across the dose range tested
- GHRP-6 produced significant, dose-dependent ACTH and cortisol elevation; Ipamorelin did not — ACTH and cortisol remained at or near baseline across all Ipamorelin doses tested
- Prolactin elevation, observed with GHRP-6, was absent with Ipamorelin
- The selectivity was attributed to the N-terminal Aib substitution, leading the authors to propose Ipamorelin as “the first selective GH secretagogue”
Subsequent research confirmed these findings in rat models (Henriksen et al. 1999, Hansen et al. 1999), establishing Ipamorelin’s selectivity profile as a reproducible pharmacological property rather than a model-specific artefact.
Ipamorelin vs GHRP-2: Selectivity in Research Applications
| Parameter | Ipamorelin | GHRP-2 |
|---|---|---|
| Amino acids | 5 (pentapeptide) | 6 (hexapeptide) |
| N-terminal residue | Aib (α-aminoisobutyric acid) | His (histidine) |
| GH release | Robust | Robust |
| Cortisol/ACTH elevation | Negligible (Raun 1998) | Significant |
| Prolactin elevation | Negligible | Present |
| Hunger stimulation | Minimal | Present (ghrelin-like) |
| Research selectivity | GH-selective | GH + HPA axis |
| MW | 711 Da | 817 Da |
Ipamorelin + CJC-1295+DAC Research Stack
Dual-pathway GH axis model. Both compounds available. 99%+ purity. Batch COA.
Frequently Asked Questions
What makes Ipamorelin selective compared to GHRP-2?
The N-terminal Aib (α-aminoisobutyric acid) substitution in Ipamorelin modifies the receptor engagement geometry at GHS-R1a in a way that preferentially activates somatotroph-expressed receptors while avoiding corticotroph GHS-R1a activation. GHRP-2’s N-terminal histidine residue does not confer this selectivity, resulting in co-activation of ACTH and cortisol pathways alongside GH release. Raun et al. (1998) identified this structural basis for selectivity as a definitive pharmacological finding, describing Ipamorelin as “the first selective growth hormone secretagogue.”
How does Ipamorelin interact with CJC-1295 in research models?
CJC-1295+DAC activates GHRH-R (Gs/cAMP pathway) and Ipamorelin activates GHS-R1a (Gq/calcium pathway). These two second-messenger cascades converge synergistically at pituitary somatotrophs: elevated cAMP from GHRH-R sensitises cells to the calcium trigger from GHS-R1a activation. Additionally, Ipamorelin’s hypothalamic GHS-R1a activity suppresses somatostatin, removing the GH release brake. Together, the combination produces substantially greater GH amplitude than either compound alone — typically documented as 3–10x amplification in research models.
What is the serum half-life of Ipamorelin?
Ipamorelin’s estimated serum half-life in research models is approximately 30–60 minutes. The D-form amino acids at positions 3 and 4 confer proteolytic resistance compared to entirely L-form peptides, but the compound does not carry a half-life extension modification comparable to the DAC linker on CJC-1295. This short half-life means Ipamorelin produces discrete GH pulses at each administration time point, rather than the sustained background GHRH-R engagement that CJC-1295+DAC provides.
Is Ipamorelin the same as GHRP-2?
No. Both are GHS-R1a agonists but are structurally distinct (5 vs 6 amino acids, different N-terminal residue) and produce meaningfully different hormonal profiles. Ipamorelin produces GH-selective release; GHRP-2 co-activates cortisol, ACTH, and prolactin. They are not interchangeable in research designs where secondary hormonal effects are a variable of interest. In research designs focused solely on GH axis characterisation without regard to secondary hormonal outcomes, the GH responses are broadly comparable in magnitude.
Is Ipamorelin legal to purchase in the UK?
Ipamorelin is not listed as a controlled substance under the Misuse of Drugs Act 1971 and does not fall within the scope of Psychoactive Substances Act 2016 enforcement for legitimate research chemical suppliers. It is available in the UK as a research chemical for in vitro and preclinical laboratory research only. It is not MHRA-approved for human therapeutic use and must not be used for human consumption.
Source Research-Grade Ipamorelin
10MG vials. 99%+ HPLC verified. Batch COA. UK-based. Crypto and bank transfer accepted.
Summary
Ipamorelin occupies a distinct position in GH secretagogue research: it delivers robust GHS-R1a-mediated GH release with a selectivity profile unmatched by earlier hexapeptide compounds. The elimination of ACTH, cortisol, and prolactin co-stimulation — established in Raun et al. (1998) and replicated across rodent and pig models — makes Ipamorelin the methodologically preferred GHS when research objectives require clean GH-specific signal isolation. Its 5-amino-acid backbone, proteolytically stabilised by D-form residues, gives a half-life of approximately 30–60 minutes in research models.
The synergistic relationship between Ipamorelin and CJC-1295+DAC — dual activation of GHRH-R and GHS-R1a — is the most consequential research application of the compound. By engaging two mechanistically orthogonal signalling cascades simultaneously, the combination produces GH amplification of 3–10-fold compared to either compound alone, making it the standard two-compound model for maximal, physiologically-patterned GH axis activation research.
In the UK, Ipamorelin is available as a research chemical with a clear regulatory position under the Misuse of Drugs Act 1971 — it is not a controlled substance. Researchers should source HPLC-verified material with batch-specific COA documentation to ensure compound identity and purity for reliable experimental results.
References
- Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 139(5):552–561. DOI: 10.1530/eje.0.1390552
- Henriksen DB, et al. (1999). Application of the principle of superposition to the pharmacokinetics of ipamorelin. Pharmaceutical Research. 16(11):1670–1675.
- Hansen BS, et al. (1999). In vitro and in vivo effects of the growth hormone secretagogues ipamorelin and L-692,585. Journal of Endocrinology. 163(3):531–541.
- Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 54(12):1316–1329.
- Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273(5277):974–977.